Literature DB >> 23123553

Triggers for surgical referral in degenerative mitral valve regurgitation.

Shinobu Itagaki1, David H Adams, Anelechi C Anyanwu.   

Abstract

Degenerative mitral valve disease is the most common etiology of mitral regurgitation in developed countries. Degenerative mitral valve disease should be distinguished from other valvular disease because most of the lesions caused by degenerative changes are amenable to valve repair as opposed to replacement, and successful durable repair with optimal timing can maintain the patient's normal life expectancy. Despite dramatic surgical progress in degenerative mitral valve repair over the past few decades and detailing of surgical indications in established practice guidelines, prevailing data suggest a significant number of patients are still not referred for surgery in a timely fashion or are even denied for surgery for inappropriate reasons. This article reviews the current surgical triggers which all practicing cardiovascular specialists should be familiar with and which should prompt immediate surgical referral.

Entities:  

Mesh:

Year:  2012        PMID: 23123553     DOI: 10.1253/circj.cj-12-0972

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  3 in total

Review 1.  Etiology of valvular heart disease-genetic and developmental origins.

Authors:  Joy Lincoln; Vidu Garg
Journal:  Circ J       Date:  2014-07-07       Impact factor: 2.993

2.  Assessment of left ventricular volumes and primary mitral regurgitation severity by 2D echocardiography and cardiovascular magnetic resonance.

Authors:  Caroline M Van De Heyning; Julien Magne; Luc A Piérard; Pierre-Julien Bruyère; Laurent Davin; Catherine De Maeyer; Bernard P Paelinck; Christiaan J Vrints; Patrizio Lancellotti
Journal:  Cardiovasc Ultrasound       Date:  2013-12-27       Impact factor: 2.062

3.  Pathophysiology of valvular heart disease.

Authors:  Y I Zeng; Rongrong Sun; Xianchi Li; Min Liu; Shuang Chen; Peiying Zhang
Journal:  Exp Ther Med       Date:  2016-02-05       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.